Weber-Krüger Mark, Gelbrich Götz, Stahrenberg Raoul, Liman Jan, Kermer Pawel, Hamann Gerhard F, Seegers Joachim, Gröschel Klaus, Wachter Rolf
Clinic for Cardiology and Pneumology, University of Göttingen, Göttingen, Germany.
Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany; Clinical Trial Centre, University of Würzburg, Würzburg, Germany.
Am Heart J. 2014 Oct;168(4):438-445.e1. doi: 10.1016/j.ahj.2014.06.018. Epub 2014 Jul 3.
Detecting paroxysmal atrial fibrillation (AF) in patients with ischemic strokes presenting in sinus rhythm is challenging because episodes are often short, occur randomly, and are frequently asymptomatic. If AF is detected, recurrent thromboembolism can be prevented efficiently by oral anticoagulation. Numerous uncontrolled studies using various electrocardiogram (ECG) devices have established that prolonged ECG monitoring increases the yield of AF detection, but most established procedures are time-consuming and costly. The few randomized trials are mostly limited to cryptogenic strokes. The optimal method, duration, and patient selection remain unclear. Repeated prolonged continuous Holter ECG monitoring to detect paroxysmal AF within an unspecific stroke population may prove to be a widely applicable, effective secondary prevention strategy.
Find-AFRANDOMISED is a randomized and controlled prospective multicenter trial. Four hundred patients 60 years or older with manifest (symptoms ≥24 hours or acute computed tomography/magnetic resonance imaging lesion) and acute (symptoms ≤7 days) ischemic strokes will be included at 4 certified stroke centers in Germany. Those with previously diagnosed AF/flutter, indications/contraindications for oral anticoagulation, or obvious causative blood vessel pathologies will be excluded. Patients will be randomized 1:1 to either enhanced and prolonged Holter ECG monitoring (10 days at baseline and after 3 and 6 months) or standard of care (≥24-hour continuous ECG monitoring, according to current stroke guidelines). All patients will be followed up for at least 12 months.
The primary end point is newly detected AF (≥30 seconds) after 6 months, confirmed by an independent adjudication committee. We plan to complete recruitment in autumn 2014. First results can be expected by spring 2016.
在表现为窦性心律的缺血性卒中患者中检测阵发性心房颤动(AF)具有挑战性,因为发作通常短暂、随机发生且常常无症状。如果检测到AF,口服抗凝治疗可有效预防复发性血栓栓塞。众多使用各种心电图(ECG)设备的非对照研究已证实,延长ECG监测可提高AF检测率,但大多数既定程序耗时且成本高昂。少数随机试验大多局限于隐源性卒中。最佳方法、持续时间和患者选择仍不明确。在非特定卒中人群中反复进行延长的连续动态心电图监测以检测阵发性AF可能是一种广泛适用的有效二级预防策略。
Find-AFRANDOMISED是一项随机对照前瞻性多中心试验。德国4个认证卒中中心将纳入400例60岁及以上有明显症状(症状≥24小时或急性计算机断层扫描/磁共振成像病变)且为急性(症状≤7天)缺血性卒中的患者。既往诊断为AF/心房扑动、有口服抗凝治疗的适应证/禁忌证或有明显病因性血管病变的患者将被排除。患者将按1:1随机分为强化延长动态心电图监测组(基线时、3个月和6个月后各监测10天)或标准治疗组(根据当前卒中指南进行≥24小时连续心电图监测)。所有患者将至少随访12个月。
主要终点是6个月后由独立判定委员会确认的新检测到的AF(≥30秒)。我们计划于2014年秋季完成招募。预计2016年春季可获得首批结果。